

Zelira Therapeutics Ltd

08:54 09 Nov 2020

Zelira Therapeutics partners with Emyria for autism observational trial for HOPE products

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has entered into an agreement with Emyria Ltd (ASX:EMD), to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD) treated with Zelira's HOPE™ range of products.

The observational trial will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with ASD.

Emyria is recognised as a global leader in the collection and translation of real-world patient data (RWD) and also owns and manages a national network of specialist medical clinics.

Complement existing data pack

Zelira managing director Richard Hopkins said: "We are excited to secure this agreement with Emyria to further augment our launch of HOPE™ in Australia, particularly after the successful launch of these products in the USA.

"This will be one of the largest observational medicinal cannabis studies ever undertaken in patients with ASD involving a specific range of products.

"The focused approach will generate very high-quality RWD that will complement our existing data-pack for HOPE™ and inform our global marketing strategy in realtime.

"This information will also inform the design of possible future clinical trials, reduce the risks and costs of development and accelerate the path to regulatory approval.

"The agreement builds upon our existing partnership with Emyria by further leveraging their leading RWD expertise.

"Emyria's ability to expand and adapt their model to facilitate a large observational trial highlights the strategic value of this relationship.

"These key value-adding features highlight the competitive advantages of our unique 'Launch, Learn and Develop' model, further differentiating Zelira from its global peers, and enhancing the commercialisation opportunities for the company."

Realise potential of RWD


Emyria managing director Dr Michael Winlo added: "We're delighted to be working with Zelira Therapeutics again, this time to realise the potential of our real-world evidence data products to help progress the commercialisation and regulatory understanding of Zelira's medicinal cannabis treatments.

"Partnering with clinically-focused companies, such as Zelira, further supports our model of generating high-quality

Price: 0.062

Market Cap: \$73.8 m

1 Year Share Price Graph



March 2020 September 2020 March 2021

Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.14 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets.

action@proactiveinvestors.com.au

patient data to accelerate development of improved cannabis medicines for patients with unmet needs."

Study design

The study design will facilitate strategic engagement with key stakeholders in the autism community and streamline patient access via Emyria's national network of specialist medical clinics - Emerald Clinics.

These efforts will complement and augment the recent launch of HOPE™ in the Australian market.

Under the terms of the agreement, Emyria will provide Zelira with longitudinal RWD collected from ASD patients prescribed a HOPE™ product.

Data will include patient's efficacy and safety relating to comorbidities, concomitant medications, dosing information and patient responses to HOPE™ treatment as measured using standard ASD clinical and behavioural endpoints.

Terms of the deal

Zelira will pay Emyria fees of \$115,000 in two instalments over the first six months, as well as a subscription fee for each patient enrolled in the study, up to a maximum of 150 participants.

The term of the agreement is for 12 months, with an option to extend the subscription fees on an ongoing basis.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).